Lenalidomida Tarbis

Lenalidomide, the active ingredient in Lenalidomida Tarbis, is an immunomodulatory imide drug (IMiD) presented as a tablet for oral use. It is indicated for the treatment of multiple myeloma, myelodysplastic syndromes with del(5q) deletion, and mantle cell lymphoma in adult patients, and it is formulated for oral administration under specialist supervision.

GNH USA supplies Lenalidomida Tarbis as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, oncology centres, pharmacies and clinics worldwide under stringent quality assurance protocols.

Lenalidomide is used in hematologic malignancies that rely on abnormal plasma cell proliferation or chromosomal deletions. - Multiple Myeloma: improves progression‑free survival and reduces disease burden in relapsed or refractory patients. - Myelodysplastic Syndromes with del(5q): decreases transfusion dependence and induces cytogenetic remission. - Mantle Cell Lymphoma: achieves tumor response in patients with relapsed or refractory disease.

Lenalidomide may cause a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects: - Fatigue: persistent tiredness affecting daily activities. - Diarrhea: loose stools that may be mild to moderate. - Nausea: feeling of sickness, sometimes with vomiting. - Rash: skin redness or itching. - Constipation: difficulty passing stools. - Peripheral neuropathy: tingling or numbness in extremities.

Serious or Rare Side Effects: - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Severe neutropenia: marked reduction in neutrophil count increasing infection risk. - Severe thrombocytopenia: low platelet count leading to bleeding. - Secondary primary malignancies: emergence of new cancers. - Hepatotoxicity: liver enzyme elevations or liver injury.

When prescribing lenalidomide, clinicians should observe several safety measures and monitoring requirements. - Pregnancy testing: perform before initiation and use effective contraception throughout treatment. - Thromboembolism risk: assess patient history and consider prophylactic anticoagulation. - Hematologic monitoring: regularly check complete blood counts for neutropenia and thrombocytopenia. - Renal function: adjust use in patients with impaired kidney function. - Infection vigilance: monitor for signs of infection due to immunosuppression. - Store at ambient temperature: keep tablets below 25 °C in the original container, protected from moisture and light.

Lenalidomide interacts with several agents that can alter its efficacy or increase toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inducers: may reduce plasma concentrations of lenalidomide. - Anticoagulants (warfarin, DOACs): increase risk of bleeding. - Immunosuppressants (e.g., cyclosporine): may enhance hematologic toxicity.

Moderate Interactions (Monitor Closely): - P-glycoprotein inhibitors: can raise lenalidomide levels. - Vaccines (live attenuated): risk of infection, avoid during therapy. - NSAIDs: may increase risk of renal impairment.